Login to Your Account



Poxel Adds $17M in Series B For Diabetes Drug Imeglimin

By Nuala Moran
Staff Writer

Friday, December 21, 2012
Poxel SA raised €13 million (US$17.3 million) in a Series B round that is intended to see its lead Type II diabetes treatment, imeglimin, through Phase IIb and into the arms of a commercialization partner.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription